

		EMLc	Codes ATC: H02AB02
Indication	Lymphoid leukaemia, not elsewhere classified	Code ICD11: 2C03.3	
INN	Dexamethasone		
Type de médicament	Chemical agent		
Type de liste	Liste complémentaire (EML) (EMLc)		
Formulations	Oral > Liquid: 2 mg per 5 mL (EMLc) Oral > Solid: 2 mg (EMLc) ; 4 mg Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphosphate salt)		
Historique des statuts LME	Ajouté pour la première fois en 1977 (TRS 615) Modifié en 2015 (TRS 994)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Balises	Cancer		
Wikipédia	Dexamethasone 		
DrugBank	Dexamethasone 		

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.

Rapport du comité d'experts 

